MicroRNAs and bioactive compounds on TLR/MAPK signaling in rheumatoid arthritis

Area of Science:

• Immunology
• Molecular Biology
• Genetics

Background:

• Rheumatoid arthritis (RA) is a chronic autoimmune joint disease affecting 1% of the global population, leading to joint degradation and disability.
• The precise mechanisms driving RA progression are not fully understood, but aberrant microRNA (miRNA) expression is increasingly recognized as a significant factor.
• miRNAs regulate inflammatory processes implicated in RA pathogenesis, including the production of key cytokines and matrix metalloproteinases.

Purpose of the Study:

• To review the molecular mechanisms of miRNA involvement in rheumatoid arthritis.
• To elucidate the role of the Toll-like receptor (TLR) dependent mitogen-activated protein kinase (MAPK) signaling pathway in RA.
• To correlate dysregulated miRNAs within the TLR/MAPK pathway with bioactive compounds for potential RA therapeutic strategies.

Main Methods:

• Literature review of recent findings on miRNA and TLR/MAPK signaling in RA.
• Analysis of molecular mechanisms underlying miRNA-mediated inflammation in RA.
• Identification of bioactive compounds that modulate TLR/MAPK signaling pathways relevant to RA.

Main Results:

• Aberrant miRNA expression significantly contributes to the pathogenesis of rheumatoid arthritis.
• The TLR/MAPK signaling pathway is critically involved in mediating the pathological features of RA.
• Specific bioactive compounds show potential in modulating aberrant miRNA expression and the TLR/MAPK pathway.

Conclusions:

• Understanding miRNA regulation within the TLR/MAPK pathway is crucial for RA pathogenesis.
• Targeting miRNA expression with bioactive compounds presents a potent therapeutic avenue for RA treatment by suppressing the TLR/MAPK pathway.